Spiriva Respimat (Tiotropium Bromide) Patent Expiration, LOE Window & CMS Spending
Spiriva Respimat (Tiotropium Bromide) by Boehringer Ingelheim: FDA Orange Book LOE 2031-04-16, 1 AB generics, $1.13B 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N021936 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-04-16 |
| Orange Book Patents (*PED Extensions) | 4 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $1.13B |
| 2024 Medicare Part D Spend | $877.2M |
| 2024 Medicaid Spend | $254.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.